Press Releases
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Sep 29, 2014
New data for the Lotus™ Valve System announced at PCR London Valves 30-Day outcomes for the 250 patients enrolled in REPRISE II Extended Cohort trial were presented by Prof Ian Meredith at PCR...
-
Sep 29, 2014Neue Daten für das Lotus™-Klappensystem beim PCR London Valves Kongress vorgestellt
Prof. Ian Meredith hat im Rahmen des PCR London Valves Kongresses am Montag 30-Tage-Daten der REPRISE-II-Extension vorgestellt, die 250 Patienten einschließt. REPRISE II, eine Studie zur...
-
Sep 25, 2014Nuovi dati per la valvola Lotus™ presentati al congresso PCR London Valves
I dati a 30 giorni per i 250 pazienti arruolati nello studio di coorte esteso REPRISE II sono stati presentati il 29 settembre dal Professor Ian Meredith nell'ambito del congresso PCR London...
-
Sep 23, 2014Data From REPRISE III Clinical Trial Designed to Support U.S. Regulatory Approval
Boston Scientific Corporation (NYSE: BSX) has initiated the REPRISE III clinical trial, a pivotal study to evaluate the safety and effectiveness of the Lotus™ Valve System in patients with...
-
Sep 18, 2014Vercise DBS System is the First DBS System Offering Precise Neural Targeting and a 25-Year Battery Life
Boston Scientific Corporation (NYSE: BSX) has received CE Mark for the Vercise™ Deep Brain Stimulation (DBS) System for the treatment of tremor, including the most common form of this movement...